Latest Headlines

Latest Headlines

One foot in biotech graveyard, NeuroSearch is calling it quits

Three years ago Denmark's NeuroSearch had more than 200 busy employees working on a pipeline of new drugs, including a late-stage drug for Huntington's disease. Today, it's laying off most of the small group of staffers who remain, whittling the employee roster to a bare skeleton as it prepares to auction off the furniture and its remaining CNS drug assets.

Neurosearch decimates staff as it circles wagons on Huntington's drug

Hunkering down to get its experimental treatment for Huntington's disease through Phase III, Denmark's troubled NeuroSearch has outlined plans to slash its workforce from 200 to some 35 employees

NeuroSearch shares nosedive after FDA blocks Huntington's drug app

Shares of NeuroSearch ($NEUR) took a nosedive after the Danish biotech reported that its application for an experimental Huntington's drug had run into a serious roadblock at the FDA. Regulators are

NeuroSearch cuts 20% of jobs, focuses on Huntington's drug

Looking to save $17.35 million annually, Denmark's NeuroSearch announced today that 's cutting 20 percent of its workforce. The changes come as NeuroSearch attempts to throw resources behind

Neurosearch shares soar on promising Ph3 Huntington's data

Investors swiftly bid up the value of Neurosearch (NEUR) shares by a whopping 81 percent after hearing that the Danish biotech's Phase III trial of a new drug for Huntington's disease demonstrated

NeuroSearch snags $46M in CNS pact with J&J

Denmark's NeuroSearch has snared a development pact with J&J's Janssen Pharmaceutica that comes with about $46 million in guaranteed payments. Under the deal, NeuroSearch will help advance and

Astellas hands back rights to NeuroSearch program

Japan's Astellas won't be developing an experimental new drug for schizophrenia it in-licensed from Denmark's NeuroSearch. The Danish company says that Astellas has returned the global rights to

NeuroSearch, Lilly ink multimillion-dollar CNS deal

NeuroSearch is getting a capital injection of $22 million after signing a new R&D pact with Eli Lilly. Lilly is providing $5 million of that as an upfront fee and $17 million in an equity

NeuroSearch feels the pain as drug flunks Phase II

Denmark's NeuroSearch says it's shelving a pain program after a mid-stage trial for the experimental pain med ABT-894 failed to deliver the data it was hoping for. Researchers recruited 404 patients

NeuroSearch touts Phase II tesofensine data

In a study published in The Lancet, Europe's NeuroSearch announced strong Phase II for tesofensine, the company's anti-obesity compound. The hunger-suppressing drug produced a weight loss twice that